|2.||Rosacea (Acne Rosacea)
|1.||Charbel Issa, Peter: 13 articles (01/2016 - 01/2007)|
|2.||Holz, Frank G: 13 articles (01/2016 - 01/2007)|
|3.||Scholl, Hendrik P N: 10 articles (05/2013 - 01/2007)|
|4.||Gillies, Mark C: 8 articles (09/2013 - 02/2009)|
|5.||Pope, Janet E: 7 articles (08/2015 - 12/2008)|
|6.||Bird, Alan C: 6 articles (04/2015 - 03/2008)|
|7.||Peto, Tunde: 6 articles (04/2015 - 03/2008)|
|8.||Baron, Murray: 6 articles (06/2014 - 05/2010)|
|9.||Goldman, Mitchel P: 6 articles (08/2012 - 01/2002)|
|10.||Dover, Jeffrey S: 6 articles (09/2007 - 01/2002)|
01/01/2003 - "Millisecond pulse duration 1064-nm Neodymium:YAG (Nd:YAG) lasers have been shown to be effective in the treatment of some lower leg telangiectases. "
04/01/1999 - "The 532 nm, 10 ms pulse duration, frequency-doubled Neodymium:YAG laser is safe and effective for treating spider veins of the lower extremities less than 0.75 mm in diameter, in patients with Fitzpatrick skin Types I-III."
09/01/2012 - "A group of 20 healthy women aged between 24 and 47 years (mean±sem 37.05 ± 1.47) with lower leg telangiectasia without clinical vein insufficiency, previously investigated by echo colour Doppler sonography, were recruited and were treated with neodymium:YAG laser (mean±sem 2.5 ± 0.11 sessions). "
09/01/2012 - "Neodymium:YAG laser treatment of lower leg telangiectasia: a new minimally invasive approach."
02/01/2006 - "Optimal pulse durations for the treatment of leg telangiectasias with a neodymium YAG laser."
10/01/2013 - "This case implies that the patients with non-proliferative macular telangiectasia type 2 should be followed carefully for proliferative transformation, and intravitreal bevacizumab treatment seems to be effective for proliferative macular telangiectasia type 2. "
10/01/2010 - "The aim of this study is to evaluate the long-term efficacy of intravitreal bevacizumab (IVB) for eyes with non-proliferative idiopathic macular telangiectasia type 2 (IMT2) and acute vision loss. "
10/01/2011 - "In proliferative macular telangiectasia Type 2, bevacizumab caused involution of neovascularization and improved visual acuity."
07/01/2010 - "To investigate the efficacy of intravitreal bevacizumab for the treatment of idiopathic macular telangiectasia (IMT). "
07/01/2014 - "[Intravitreal bevacizumab in the treatment of idiopathic juxtafoveal telangiectasis type I]."
11/01/2005 - "Other findings included the presence of hyperreflectivity in the middle or inner retinal layers, suggesting retinal pigment epithelium proliferation and migration corresponding to the stellate foci of pigmentation in stage 4 and features of choroidal or subretinal neovascular membrane in stage 5. The optical coherence tomography findings in group 2A idiopathic juxtafoveolar telangiectasis were characteristic and may be helpful in making the diagnosis and defining, as far as possible, the anatomical staging."
01/01/2015 - "This study also provides insight into the nature of the retinal vascular lesions that likely represent a clinical correlate for the formation of retinal telangiectasia or Coats-like vasculopathy in patients with CRB1 mutations that are thought to depend on such genetic modifiers. "
09/01/1996 - "To study the natural history and retinal findings associated with the intraretinal and subretinal fibrovascular tissues that develop in the late phases of bilateral juxtafoveal telangiectasis. "
04/15/2015 - "Potential molecular targets linking RMG/photoreceptor interaction with the development of retinal telangiectasia are identified. "
04/15/2015 - "A new CRB1 rat mutation links Müller glial cells to retinal telangiectasia."
01/01/1987 - "This study documents the treatment and long-term follow-up of telangiectasias of the face and neck with the argon laser. "
03/01/1998 - "Dermatology is another field where argon laser has shown great efficiency: hemangyomas, telangiectasias, tattoos, small benign and malignant tumours are amenable to argon laser treatment. "
11/01/1994 - "Comparison of the argon tunable dye laser with the flashlamp pulsed dye laser in treatment of facial telangiectasia."
01/01/1993 - "This prospective study compares the efficacy, side effects, and patient acceptance of the flashlamp pulsed dye laser (FPDL) with the argon tunable dye laser with robotized handpiece (ATDL/H) for facial telangiectasias. "
01/01/1993 - "Comparison of the flashlamp pulsed dye laser with the argon tunable dye laser with robotized handpiece for facial telangiectasia."
06/01/1999 - "The purpose of this study was to compare the efficacy of four different frequency-doubled neodymium:yttrium-aluminum-garnet (FD Nd:YAG) laser (532 nm) systems for the treatment of facial arteriolar telangiectases. "
07/01/2013 - "To evaluate the safety and efficacy of a microsecond 1,064-nm neodymium-doped yttrium aluminum garnet (Nd:YAG) laser for the treatment of facial telangiectasias. "
07/01/2013 - "Successful treatment of facial telangiectasias using a micropulse 1,064-nm neodymium-doped yttrium aluminum garnet laser."
01/01/2006 - "To investigate the effectiveness of a variable-pulse neodymium:yttrium-aluminum-garnet (Nd:YAG) laser using a small spot size in the treatment of facial telangiectasias. "
04/01/2012 - "To compare the efficacy of conventional sclerotherapy and neodymium-doped yttrium aluminum garnet (Nd:YAG) laser in the treatment of leg telangiectasias. "
|6.||polidocanol (Laureth)FDA Link
06/01/2014 - "The clinical application of polidocanol, already in clinical practice for occlusal of telangiectasias, for surgical delay appears feasible."
08/01/2012 - "Sixty-three subjects' legs were randomized to receive treatment with polidocanol (POL) or hypertonic saline (HS) for telangiectasias and reticular leg veins. "
01/01/2002 - "Tortuous veins and telangiectases on the chest of three patients were treated with either STS 0.25-0.50% or polidocanol 0.75% with a follow-up of 2-9 years. "
01/01/1990 - "Reply to 'Treatment of Essential Telangiectasia': Use of Polidocanol."
04/01/1989 - "Treatment of essential telangiectasia: effects of increasing concentrations of polidocanol."
01/01/2013 - "Among diverse laser for skin treatment, copper bromide laser is a very effective, safe, and well tolerated treatment for facial telangiectasia at various energy levels and the most important thing of the copper bromide laser device is that the stability of the energy. "
11/01/2012 - "This study showed that the copper bromide laser is a very effective, safe, and well tolerated treatment for facial telangiectasia at all four tested energy levels."
01/01/1997 - "The copper bromide laser is a safe and effective modality for the treatment of the majority of facial telangiectasia. "
01/01/1997 - "The objective of this study was to ascertain the role and efficacy of the copper bromide laser on treatment of a variety of facial telangiectasia. "
11/01/2012 - "Copper bromide laser for facial telangiectasia: a dose response evaluation."
|8.||ranibizumab (Lucentis)FDA Link
05/01/2012 - "To evaluate the safety and preliminary efficacy of intravitreal ranibizumab for nonneovascular idiopathic macular telangiectasia Type 2. Single-center, open-label Phase II clinical trial enrolling five participants with bilateral nonneovascular idiopathic macular telangiectasia Type 2. Intravitreal ranibizumab (0.5 mg) was administered every 4 weeks in the study eye for 12 months with the contralateral eye observed. "
10/01/2014 - "To evaluate the effects of 0.3 mg or 0.5 mg of ranibizumab in eyes with macular telangiectasia type 2 without subretinal neovascularization. "
10/01/2014 - "Ranibizumab for macular telangiectasia type 2 in the absence of subretinal neovascularization."
01/01/2013 - "To report the anatomic and functional outcomes of intravitreal ranibizumab in idiopathic parafoveal telangiectasia (IPT). "
05/01/2012 - "Intravitreal ranibizumab administered monthly over a time course of 12 months is unlikely to provide a general and significant benefit to patients with nonneovascular idiopathic macular telangiectasia Type 2."
|9.||glucuronyl glucosamine glycan sulfate (Vessel)IBA
07/01/2008 - "Telangiectasia improved from LPDL and IPL treatments with superior vessel clearance from LPDL treatments (postoperative side-to-side evaluations, patient self-assessments, P<or=0.031, 3, 6 months). "
01/01/2012 - "Pathological vascular changes may also include less well characterized traits of vascular remodeling that are non-neovascular, such as vessel pruning and the emergence of dilated and tortuous vessel phenotypes (telangiectasis). "
08/01/2011 - "From the telangiectasia mask containing candidate vessel-like structures, shape, size and normalized count features are computed to facilitate the discrimination of benign skin lesions from BCCs with telangiectasia. "
02/01/2010 - "The LPDL was superior in the overall reduction of telangiectasias by blinded photographic evaluations: Excellent clearance (75% to 100% vessel clearance) was found in 18 patients treated with LPDL (46%) and in 11 patients treated with IPL (28%) (P = 0.01). "
01/01/2006 - "The analyzed parameters of the face were morphological (background color, vessel irregularities) and quantitative (polygonal net perimeter, telangiectasia, and vessel diameters). "
05/01/2009 - "The use of PDT for photorejuvenation is a relatively new application of this technology, which has shown promise in improving the appearance of fine lines, pigmentary variation, and telangiectasias. "
07/01/2003 - "This case indicates that PDT for subretinal neovascularization due to bilateral idiopathic acquired juxtafoveolar telangiectasis may achieve partial short-term neovascular membrane closure and improvement in visual acuity."
11/01/2004 - "To analyze the results of photodynamic therapy (PDT) in bilateral acquired parafoveal telangiectasis. "
01/01/2009 - "Resolution of macular edema in idiopathic juxtafoveal telangiectasis using PDT."
01/01/1996 - "Photodynamic therapy (PDT) was used to stop life-threatening hemoptysis from bleeding hereditary telangiectasia in bronchi in a 42-year-old man with a 4-year history of repeated embolotherapies, tracheostomies, and ventilator dependence. "
02/01/2010 - "This study was based on two specific types of laser and IPL equipment, which effectively clear telangiectasias; however, the most beneficial outcome was from the LPDL."
04/01/2007 - "Both the 595-nm and the 532-nm pulsed lasers are highly effective in the treatment of facial telangiectasia and redness. "
06/01/2007 - "Clinical assessment 6 months after the last treatment with the Fraxel SR laser revealed marked improvement in the clinical appearance of the matted telangiectasias. "
12/01/2000 - "Recent studies have demonstrated good clearance of leg telangiectasia and reticular veins using a variety of laser systems with deeper penetrating, near-infrared wavelengths and higher fluences in conjunction with various epidermal cooling methods. "
01/01/2006 - "Variable-pulse 1,064 nm wavelength lasers have been used with good effectiveness on leg telangiectasias and reticular veins and have shown promising results on facial telangiectasias as well. "
01/01/2010 - "ULPDL treatment delivered using a 3 mm x 10 mm elliptical spot was non-purpuric and highly effective in the treatment of nasal telangiectasia resistant to KTP laser and PDL."
11/01/2000 - "A single treatment with a 755-nm, 3-millisecond alexandrite laser at high fluence in conjunction with cryogen skin cooling produced excellent clearance of telangiectasia and reticular veins of the leg with minimal adverse effects."
06/01/2011 - "Both the 1064-nm Nd:YAG and KTP lasers are effective in the treatment of lower extremity telangiectases. "
10/01/2008 - "Pulsed Nd:YAG laser therapy (1,064 nm) appears to be an effective and safe treatment option for hereditary haemorrhagic telangiectasia on the skin of face and extremities."
01/01/2003 - "The millisecond pulse duration 1064-nm Nd:YAG laser is effective for treatment of facial telangiectases."
07/01/2003 - ": Pulsed-dye laser treatment has been shown to be highly effective for the treatment of facial telangiectasia. "
10/01/1997 - "The flashlamp-pumped pulsed dye laser (585 and 577 nm) has proven to be a very effective and safe treatment option in the therapy of essential telangiectasias (ETE). "
07/01/2003 - "Significantly, the variable-pulse pulsed-dye laser offers patients the option of effective treatment of some telangiectasia without bruising."
02/01/2012 - "Facial telangiectasia and other vascular lesions have historically been effectively treated with the pulsed dye laser (PDL). "
01/01/1998 - "Preliminary results indicate that pulsed dye lasers (PDL) with 1.5 ms pulsewidth and 595 nm wavelength are effective in the treatment of leg telangiectasia. "
05/01/2012 - "Developed after observing the good results achieved by perioperative sclerotherapy of telangiectasias during ambulatory phlebectomy, the START technique is an effective and economic treatment of therapy-resistant telangiectasias, although because the rate of complications is higher than with usual sclerotherapy of C1 veins, it should be performed only by experienced phlebologists and only on therapy-refractory vessels."
03/01/2004 - "This study shows that CG is superior to POL solution and foam for sclerotherapy of leg telangiectasias."
01/01/2002 - "Finally, the tortuous veins and telangiectases of the chest improved by 50-100% with sclerotherapy. "
10/01/2012 - "Our study revealed that the most efficient method in terms of telangiectasias clearance is sclerotherapy. "
06/01/2011 - "Compression versus sclerotherapy for patients with isolated refluxing reticular veins and telangiectasia: a randomized trial comparing quality-of-life outcomes."
10/01/2009 - "While both 532 and 940 nm diode laser produced significant improvement in facial telangiectasias, greater efficacy was found with 940 nm as well as a significantly more tolerable side effect profile. "
03/01/2009 - "A new 980-nm diode laser effectively treats facial telangiectasias without any observed complications."
02/01/2001 - "Effective treatment of leg vein telangiectasia with a new 940 nm diode laser."
02/01/2001 - "In this preliminary study a 940 nm diode laser was shown to be safe and effective for the treatment of leg vein telangiectasia."
10/01/2009 - "Randomized controlled trial: Comparative efficacy for the treatment of facial telangiectasias with 532 nm versus 940 nm diode laser."